Paradigm Biopharmaceuticals Ltd. has released a press release.
June 2026 Quarterly Activities Report & Appendix 4C
Earlier from Paradigm Biopharmaceuticals
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- Drawdown of Tranche 4 under the Convertible Note Facility
- PAR Completes Enrolment in Pivotal Phase 3
- Results of Share Purchase Plan